The European Union has approved a new embolization product from BioSphere Medical. Called HepaSpheres, these microscopic medgadgets choke off tumor blood vessels, buying patients valuable time:
Liver cancer is one of the most prevalent forms of cancer worldwide. Although surgical removal of the tumor is the best treatment option for liver cancer, and is a potentially curative approach, the vast majority of patients are not eligible for surgery. Currently, embolotherapy is used as a palliative treatment to extend and improve the quality of life in patients whose liver cancer is at a state that is too advanced for surgical cure. The Company’s HepaSphere product is designed for use in these embolotherapy procedures to treat hypervascularized tumors, such as those found in the liver.
More at BioSphere Medical…